Maggs J L, Tingle M D, Kitteringham N R, Park B K
Department of Pharmacology and Therapeutics, University of Liverpool, U.K.
Biochem Pharmacol. 1988 Jan 15;37(2):303-11. doi: 10.1016/0006-2952(88)90733-2.
The enzymic and non-enzymic formation of protein-arylating intermediates from amodiaquine (AQ,7-chloro-4-(3'-diethylamino-4'-hydroxyanilino) quinoline), an anti-malarial associated with agranulocytosis and liver damage in man, was studied in vitro. [14C]AQ in phosphate buffer, pH 7.4, under air was autoxidized to a reactive derivative(s) which possessed characteristics indicative of a semiquinone/quinone imine: reduction by NADPH and ascorbic acid, conjugation with thiols and irreversible binding to microsomal and soluble proteins. Cysteinyl SH groups were major sites of arylation. Radiolabelled material irreversibly bound to HSA after 24 hr and to human liver microsomes after 4 hr represented 26.5 +/- 1.8% and 31.4 +/- 0.6% (means +/- SD, N = 3) of incubated [14C]AQ (10 microM), respectively. The quinone imine of AQ(AQQI) was synthesized, and displayed the same oxidative and electrophilic reactions as the product(s) of AQ's autoxidation. A water-soluble product formed in buffered solutions of AQ and N-acetylcysteine was identified as an AQ mercapturate by comparison with an adduct prepared from synthetic AQQI. Irreversible binding of [14C]AQ was inhibited by a radical scavenger; this indicated that the semiquinone imine contributed to the binding. Although AQ was extensively de-ethylated by human liver microsomes, oxidation by cytochrome P-450 did not appear to be principally responsible for its activation and irreversible binding in microsomal incubations. AQ was oxidized to protein-arylating intermediates by horseradish peroxidase. It also formed reactive derivatives, possibly N-chloro compounds, in chlorine solutions. These findings indicated that AQ can give rise to chemically reactive species by at least three distinct mechanisms, viz. autoxidation in neutral solution under air, peroxidase-catalyzed oxidation and N-chlorination. Formation of such species in liver and myeloid cells might be responsible for the adverse reactions associated with AQ.
阿莫地喹(AQ,7-氯-4-(3'-二乙氨基-4'-羟基苯胺基)喹啉)是一种与人类粒细胞缺乏症和肝损伤相关的抗疟药,本文对其在体外酶促和非酶促形成蛋白质芳基化中间体的过程进行了研究。在pH 7.4的磷酸盐缓冲液中,[14C]AQ在空气中自氧化生成一种具有半醌/醌亚胺特征的反应性衍生物:可被NADPH和抗坏血酸还原,与硫醇结合,并与微粒体和可溶性蛋白质不可逆结合。半胱氨酸的巯基是主要的芳基化位点。24小时后不可逆结合到HSA上以及4小时后不可逆结合到人类肝脏微粒体上的放射性标记物质分别占孵育的[14C]AQ(10微摩尔)的26.5±1.8%和31.4±0.6%(平均值±标准差,N = 3)。合成了AQ的醌亚胺(AQQI),其显示出与AQ自氧化产物相同的氧化和亲电反应。通过与由合成AQQI制备的加合物比较,鉴定出在AQ和N-乙酰半胱氨酸的缓冲溶液中形成的一种水溶性产物为AQ巯基尿酸。自由基清除剂可抑制[14C]AQ的不可逆结合;这表明半醌亚胺促成了这种结合。虽然AQ被人类肝脏微粒体广泛脱乙基,但细胞色素P-450的氧化似乎不是其在微粒体孵育中活化和不可逆结合的主要原因。AQ被辣根过氧化物酶氧化为蛋白质芳基化中间体。它在氯溶液中也形成反应性衍生物,可能是N-氯化合物。这些发现表明,AQ可通过至少三种不同机制产生化学反应性物种,即空气中中性溶液中的自氧化、过氧化物酶催化的氧化和N-氯化。在肝脏和髓细胞中形成此类物种可能是与AQ相关的不良反应的原因。